Dr. Steve Hahn brings two decades of healthcare strategy, clinical experience, and commercialization know-how to Singletto's strategic efforts.
As the former FDA Commissioner, Steve led a 17,000+ person team at the FDA which regulates approximately 20% of consumer spending in the United States. He oversaw COVID-19 and non-COVID-19 regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
He served in various executive leadership roles at The University of Texas MD Anderson Cancer Center from 2015-2019, including Chief Medical Executive, Chief Operating Officer, and Deputy President. Steve led the 1,200+ employee and physician staff in clinical and academic operations, as well as clinical trials and education. Steve worked within national and international clinical networks; managed strategic industry ventures and drug development platforms; and supported the financial and operational organization of the $9B research-driven patient care organization.
Now, in leadership at Flagship Pioneering, Steve serves as Chief Medical Officer of its Preemptive Medicine and Health Security Initiative.
As a clinician board certified in medical oncology and radiation oncology from 1984-2017, Steve focused his clinical research on the evaluation of drug/radiation combinations, and proton and photodynamic therapies in cancer treatment. This, combined with his recent oversight of the U.S. regulatory response to COVID-19, led to his desire to work with Singletto to bring the principles of photodynamic therapy to the global fight against deadly pathogens like SARS-CoV-2. He has authored more than 220 peer-reviewed original research articles and has vast experience in medical product development.